| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8565039fe3ab9e9b7af5ec29ab679f2a |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P33-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1709
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-472 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P33-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-37
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-36 |
| filingDate |
2003-04-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2acacec9515708abef2321321e557440
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aae1b21e24ee7f66a0b0d6d33f1ba832
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a2178d88c8b70dab08a29a8f37f691ac
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2d4a41fc0a2f030af45039a2c28bbc98
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9f9bac15bb204a0dfa62ef84710f41ce |
| publicationDate |
2003-11-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-2483441-A1 |
| titleOfInvention |
Mannose binding lectin and uses thereof |
| abstract |
The present inventors have shown that MASP-depleted MBL is able to recruit MASPs from plasma and successfully activate the complement cascade. Furthermore, it has been discovered that MBL purified as a complex has limit ed ability to activate the complement cascade when compared to MASP-depleted MB L. Accordingly, the present invention provides a pharmaceutical composition comprising an isolated non-recombinant mannose binding lectin (MBL) substantially free from activated MBL associated serine proteases (MASPs) together with a pharmaceutically acceptable carrier or diluent. Also provide d is a method of treating a subject in need of MBL comprising administering to the subject an effective amount of a pharmaceutical composition of the invention. |
| priorityDate |
2002-04-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |